Liraglutide in adolescents with simple obesity and gastrointestinal comorbidities: treatment experience

Liraglutide in adolescents with simple obesity and gastrointestinal comorbidities: treatment experience

BACKGROUND: Liraglutide was approved for treatment of obesity in children and adolescents since 12 years. Due to gastrointestinal (GI) side effects not all patients reach maximal dose; this can affect the efficacy of obesity treatment.AIM: To study efficacy and tolerability of liraglutide in adolesc...

Full description

Bibliographic Details
Main Authors:	A. V. Vitebskaya, A. V. Popovich
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2023-07-01
Series:	Ожирение и метаболизм
Subjects:	anti obesity drugs liraglutide adolescents gastrointestinal diseases
Online Access:	https://www.omet-endojournals.ru/jour/article/view/12922

Similar Items

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Alejandra Cornejo-Estrada, et al.
Published: (2023-01-01)

Liraglutide and Exercise: A Possible Treatment for Obesity?
by: Ana Paula Azevêdo Macêdo, et al.
Published: (2022-08-01)

Ejaculate quality indicators of men with asthenozoospermia and asthenoteratozoospermia by treatment of obesity with liraglutide
by: D. N. Bobkov, et al.
Published: (2021-10-01)

Comparison of the effects of liraglutide and sibutramine in obese patients
by: G. A. Matveev, et al.
Published: (2021-07-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity
by: Vladimir Ivanovich Kudinov, et al.
Published: (2011-06-01)

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
by: Yan Tong, et al.
Published: (2023-04-01)

Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Joshuan J. Barboza, et al.
Published: (2022-05-01)

Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients
by: Gennaro Martines, et al.
Published: (2023-08-01)

Lifestyle in children and adolescents with obesity: results of the survey of patients and their parents
by: Alisa V. Vitebskaya, et al.
Published: (2016-07-01)

Liraglutide Treatment in a Morbidly Obese Adolescent with a MC4R Gene Variant: Side Effects Reduce Success
by: Emine Çamtosun, et al.
Published: (2023-06-01)

Impairment of carbohydrate metabolism in children and adolescents with obesity
by: A. V. Vitebskaya, et al.
Published: (2021-08-01)

Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results
by: Sandro La Vignera, et al.
Published: (2023-01-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
by: K. A. Komshilova, et al.
Published: (2018-03-01)

EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS
by: K. A. Komshilova, et al.
Published: (2017-12-01)

Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy
by: Mohammad Jamal, et al.
Published: (2024-02-01)

Liraglutide Drug Loading with Double Layered Hydroxide- Synthesis and Characterization
by: Sevan Adeeb Doshan, et al.
Published: (2020-06-01)

Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması
by: Murat Kose, et al.
Published: (2023-09-01)

Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review
by: Aladel A, et al.
Published: (2023-10-01)

Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis
by: Haven Griffin, et al.
Published: (2022-12-01)

High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery
by: Federica Vinciguerra, et al.
Published: (2023-09-01)

GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023-01-01)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
by: Li Z, et al.
Published: (2019-09-01)

The place of central-acting drugs in the algorithms of treatment of primary obesity
by: Oksana V. Logvinova, et al.
Published: (2017-09-01)

Evaluation of the effectiveness and safety of anti-obesity drugs - an update on the current state of knowledge on available and investigational drugs
by: Katarzyna Cichoń, et al.
Published: (2023-05-01)

Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway
by: Ruibing Qi, et al.
Published: (2024-03-01)

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
by: Mariana Cornelia Tilinca, et al.
Published: (2021-06-01)

Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway
by: Alaa Alanteet, et al.
Published: (2024-01-01)

Liraglutide-Induced Hepatotoxicity
by: Yaakov Maor, et al.
Published: (2021-01-01)

Adropin – Potential Link in Cardiovascular Protection for Obese Male Type 2 Diabetes Mellitus Patients Treated with Liraglutide
by: Tina Tičinović Kurir, et al.
Published: (2020-01-01)

The Review of pharmacological treatment registered for obesity in Poland
by: Julia Wyrwał, et al.
Published: (2024-02-01)

Growth hormone treatment does not augment the anti‐diabetic effects of liraglutide in UCD‐T2DM rats
by: Michael M. Swarbrick, et al.
Published: (2023-01-01)

Review of upcoming and currently available anti-obesity drugs in Europe
by: Patryk Gryszkiewicz, et al.
Published: (2023-05-01)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
by: Miguel A. Rubio-Herrera, et al.
Published: (2023-10-01)

Pharmacological treatment of obesity in clinical practice
by: Omercan Topaloglu, et al.
Published: (2021-06-01)

Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study
by: Yu-Ning Liao, et al.
Published: (2022-09-01)

Comparison of Postprandial Insulin Levels in Withania Coagulans and Liraglutide Treated Diabetic Rats
by: Abdul Samad, Shazia Ali, Noman Sadiq
Published: (2018-12-01)

Histopathological Study of Liraglutide on Renal Deterioration Progression Induced by Doxorubicin
by: Hayder Hussein Luaibi, et al.
Published: (2019-12-01)